




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

Figure 3A






4/31



SUBSTITUTE SHEET (RULE 26)



wo 99/57535 5/31

Fig. 5A




Fig. 5B








Figure 6







SUBSTITUTE SHEET (RULE 26)

Figure 8






Figure 9




Figure 10




Figure 11




Figure 12




Figure 13






Figure 14



15/31



SUBSTITUTE SHEET (RULE 26)

Figure 16




Fig. 17A





Fig. 17B




qure 18



19A Fig.






Plus Histidine


Minus Histidine

Fig. 19B



Minus Histidine

Fig. 19C



N بتنشي 

Fig. 20A




Fig. 20B

Promyelocytic leukemia HL-60

HeLa cell S3

chronic myelogenous leukemia K-562

lymphoblastic leukemia MOLT-4

Burkitt's lymphoma Raji

colorectal adenocarcinoma SW480

lung carcinoma A549

melanoma G361


melanoma G361

22/31

## Figure 21

MGRANSRSHSSRSKSRSQSSSRSRSRSRSRKKRYRSRSRTYSRSRSRDRM	50
YSRDYRRDYRNNRGMRRPYGYRGRGRGYYQGGGGRYHRGGYRPVWNRRHS	100
RSPRRGRSRSR <u>SPKRRSVSSORSRSRSR</u> RSYRSSRSPRSSSSRSSSPYSK	150
SPVSKRRGSQEKQTKKAEGEPQEESPLKSKSQEEPKDTFEHDPSESIDEF	200
NKSSATSGDIWPGLSAYDNSPRSPHSPSPIATPPSQSSSCSDAPMLSTVH	250
SAKNTPSQHSHSIQHSPERSGSGSVGNGSSRYSPSQNSPIHHIPSRRSPA	300
KTIAPQNAPRDESRGRSSFYPDGGDQETAKTGKFLKRFTDEESRVFLLDR	350
GNTRDKEASKEKGSEKGRAEGEWEDQEALDYFSDKESGKQKFNDSEGDDT	400
EETEDYRQFRKSVLADQGKSFATASHRNTEEEGLKYKSKVSLKGNRESDG	450
FREEKNYKLKETGYVVERPSTTKDKHKEEDKNSERITVKKETQSPEQVKS	500
EKLKDLFDYSPPLHKNLDARE <u>KSTFREESPL</u> RIKMIASDSHRPEVKLKMA	550
PVPLDDSNRPASLTKDRLLASTLVHSVKKEQEFRSIFDHIKLPQASKSTS	600
esfiqhivslyhhvkeqyfksaamtlnerftsyqkateehstrqkspeih	650
RRIDISPSTLRKHTRLAGEERVFKEENQKGDKKLRCDSADLRHDIDRRRK	700
ERSKERGDSKGSRESSGSRKQEKTPKDYKEYKSYKDDSKHKREQDHSRSS	750
SSSASPSSPSSREEKESKKEREEEFKTHHEMKEYSGFAGVSRPRGTF <b>FR</b> I	800
rgrgrargvyagtnigpnnsniifqkrpkeeewdpeyipkskkyflhddr	850
DDGVDYWAKRGRGRGTFQRGRGRFNFKKSGSSPKWTHDKYQGDGIVEDEE	900
ETMENNEEKKDRRKEEKE	918

Figure 22








Figure 23









## Figure 25

pcDNA3 anti-Myc Btf<sub>s</sub> + E1B 19K anti-Myc








Figure 26





Figure 27



Charles Assets

Figure 28A




Figure 28B




Figure 29




Figure 30

pIRES-EGFP-Btfs



pIRES-EGFP



